Last updated: 2026-09-21 05:24:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Apogee Therapeutics, Inc. (APGE) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $135.09, with a market capitalization of $10.22B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $35.39 to $135.10. This page covers its latest market performance, valuation, price trends and company information.
$10.22B | |
$135.08 | |
$135.10 | |
$14.19 | |
$135.08 | |
1.49M | |
-- | |
-- | |
$135.10 | |
$35.39 | |
-- | |
-- |
Apogee Therapeutics, Inc. (APGE) last closed at $135.08 as of 2026-09-02 23:31:00, unchanged from the previous close of $135.08.
During the latest regular trading session, APGE traded between $14.19 and $135.10, with a volume of 1.49M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Apogee Therapeutics, Inc. (APGE) moved from $135.00 to $135.09, representing a gain of 0.06% ($0.09).
The stock traded between $134.81 and $135.09 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 1.74 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 100.0%
APGE is currently trading at $135.09, placing it 100.0% of the way from its 52-week low of $35.39 to its 52-week high of $135.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 261 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Apogee Therapeutics, Inc. (APGE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.